Tags

Type your tag names separated by a space and hit enter

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Eur Heart J. 2005 Jul; 26(14):1369-78.EH

Abstract

AIMS

The aim of this study was to assess the effect of the angiotensin converting enzyme inhibitor perindopril on cardiovascular events in diabetic patients with coronary artery disease.

METHODS AND RESULTS

A total of 1502 diabetic patients with known coronary artery disease and without heart failure of 12 218 overall in the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery (EUROPA) disease were randomized in a double-blinded manner to perindopril 8 mg once daily or placebo. Follow-up was for a median of 4.3 years. The primary end point was cardiovascular death, non-fatal myocardial infarction, and resuscitated cardiac arrest. Perindopril treatment was associated with a non-significant reduction in the primary endpoint in the diabetic population, 12.6 vs. 15.5%, relative risk reduction 19% [(95% CI, -7 to 38%), P=0.13]. This was of similar relative magnitude to the 20% risk reduction observed in the main EUROPA population.

CONCLUSION

Perindopril tends to reduce major cardiovascular events in diabetic patients with coronary disease in addition to other preventive treatments and the trend towards reduction was of a similar relative magnitude to that observed the general population with coronary artery disease.

Authors+Show Affiliations

Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15860521

Citation

Daly, Caroline A., et al. "The Effect of Perindopril On Cardiovascular Morbidity and Mortality in Patients With Diabetes in the EUROPA Study: Results From the PERSUADE Substudy." European Heart Journal, vol. 26, no. 14, 2005, pp. 1369-78.
Daly CA, Fox KM, Remme WJ, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J. 2005;26(14):1369-78.
Daly, C. A., Fox, K. M., Remme, W. J., Bertrand, M. E., Ferrari, R., & Simoons, M. L. (2005). The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. European Heart Journal, 26(14), 1369-78.
Daly CA, et al. The Effect of Perindopril On Cardiovascular Morbidity and Mortality in Patients With Diabetes in the EUROPA Study: Results From the PERSUADE Substudy. Eur Heart J. 2005;26(14):1369-78. PubMed PMID: 15860521.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. AU - Daly,Caroline A, AU - Fox,Kim M, AU - Remme,Willem J, AU - Bertrand,Michel E, AU - Ferrari,Roberto, AU - Simoons,Maarten L, AU - ,, Y1 - 2005/04/28/ PY - 2005/4/30/pubmed PY - 2005/10/21/medline PY - 2005/4/30/entrez SP - 1369 EP - 78 JF - European heart journal JO - Eur. Heart J. VL - 26 IS - 14 N2 - AIMS: The aim of this study was to assess the effect of the angiotensin converting enzyme inhibitor perindopril on cardiovascular events in diabetic patients with coronary artery disease. METHODS AND RESULTS: A total of 1502 diabetic patients with known coronary artery disease and without heart failure of 12 218 overall in the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery (EUROPA) disease were randomized in a double-blinded manner to perindopril 8 mg once daily or placebo. Follow-up was for a median of 4.3 years. The primary end point was cardiovascular death, non-fatal myocardial infarction, and resuscitated cardiac arrest. Perindopril treatment was associated with a non-significant reduction in the primary endpoint in the diabetic population, 12.6 vs. 15.5%, relative risk reduction 19% [(95% CI, -7 to 38%), P=0.13]. This was of similar relative magnitude to the 20% risk reduction observed in the main EUROPA population. CONCLUSION: Perindopril tends to reduce major cardiovascular events in diabetic patients with coronary disease in addition to other preventive treatments and the trend towards reduction was of a similar relative magnitude to that observed the general population with coronary artery disease. SN - 0195-668X UR - https://www.unboundmedicine.com/medline/citation/15860521/The_effect_of_perindopril_on_cardiovascular_morbidity_and_mortality_in_patients_with_diabetes_in_the_EUROPA_study:_results_from_the_PERSUADE_substudy_ L2 - https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehi225 DB - PRIME DP - Unbound Medicine ER -